Glass House Brands Cuts FY2026 Profit & Cash Guidance, Redeems Out-of-the-Money Warrants
GLASF has more than doubled off its 52-week low of $4.55.
Summary
Glass House Brands reported preliminary Q1 results and significantly lowered its full-year 2026 financial guidance for profitability and cash, while also announcing the redemption of out-of-the-money warrants.
Key Events · Earnings and Guidance · GLASF
-
FY2026 Guidance Significantly Lowered
The company revised its full-year 2026 guidance downwards, with Adjusted EBITDA now projected in the high $30 million range (down from high $40 million), gross profit margin in the mid 40% range (down from 48%), and cost of production increasing to approximately $111 per pound (from $100). Period-ending cash guidance was also reduced.
-
Mixed Preliminary Q1 2026 Results
Preliminary Q1 net revenues of $40 million exceeded guidance of $39 million, but the gross profit margin of 25% was below guidance of 29% and significantly lower than the prior year's 45%. Biomass production was ahead of guidance.
-
Redemption of Out-of-the-Money Warrants
Glass House Brands announced the redemption of 30,664,500 outstanding warrants with an exercise price of $11.50 per share. Since the current stock price ($10.39) is below the exercise price, holders will receive a small fraction of a share (0.011826 shares per warrant) if not exercised, resulting in minor dilution and cleaning up the capital structure.
Analysis · GLASF · Life Sciences
Glass House Brands reported mixed preliminary Q1 results, with revenue slightly ahead but gross profit margin significantly below guidance. More critically, the company issued a substantial downgrade to its full-year 2026 financial guidance, lowering projections for gross profit margin, cost of production, Adjusted EBITDA, and period-ending cash. This revision indicates a tougher outlook for profitability and cash generation, which is particularly concerning as the stock trades near its 52-week high. Separately, the company announced the redemption of over 30 million out-of-the-money warrants, which will result in minor dilution but cleans up the capital structure by removing a potential overhang and avoiding future cash exercise at a higher price. The negative guidance update is the primary market-moving event, signaling a challenging year ahead despite efforts to streamline the capital structure.
At the time of this filing, GLASF was trading at $10.39 on OTC in the Life Sciences sector, with a market capitalization of approximately $771.9M. The 52-week trading range was $4.55 to $10.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.